Company news
Vor Biopharma Inc. (NASDAQ:VOR) news
Vor Biopharma Inc. news releases on 6ix. Latest, Oct 5, 2026: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 4, 2026
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
September 8, 2026
Vor Bio To Participate in Upcoming September Conferences
September 1, 2026
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Vor Bio Appoints David Zaccardelli to Board of Directors
July 7, 2026
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
June 8, 2026
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 8, 2026
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 14, 2026
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Vor Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
May 5, 2026
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 29, 2026
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
March 29, 2026
Vor Bio Announces $75 Million Private Placement with TCGX
March 26, 2026
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
February 24, 2026
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
February 22, 2026
Vor Biopharma : 44th Annual J.P. Morgan Healthcare Conference Presentation (a19b30)
January 15, 2026
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
December 23, 2025
Vor Bio Announces $150 Million Private Placement
December 15, 2025
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
November 10, 2025
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 9, 2025
Vor Bio to Participate in Upcoming Investor Conferences
November 7, 2025
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
November 3, 2025
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
October 29, 2025
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
October 22, 2025
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
October 17, 2025
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
October 16, 2025
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
September 29, 2025
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
September 23, 2025
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
September 17, 2025
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
September 12, 2025
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
September 2, 2025
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
August 27, 2025
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
August 13, 2025
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
August 4, 2025
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
July 21, 2025
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
July 17, 2025
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
July 10, 2025
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2025
Vor Bio Announces $175 Million Private Placement
June 25, 2025
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
June 25, 2025
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
May 8, 2025
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
March 20, 2025
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
February 12, 2025
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
February 2, 2025